Novel in vitro model for intravitreal drug dissolution and release studies of small molecules and their long-acting formulations
Intravitreal drug delivery is essential for multiple ocular diseases. Development of intravitreal formulations requires high-quality in vivo experiments that require a large number of animals. This development can be expedited by improving in vitro testing and utilizing in vitro - in vivo correlation. We propose an in vitro approach using vitreous in a dialysis membrane to conduct these studies. The model was developed for small molecules and evaluated with drugs in solution (13 drugs in one cassette and 4 in another), and a drug suspension. For solutions, 6 out of 8 drug compounds were within 2.5-fold difference to their experimental vitreal clearances. Furthermore, we demonstrated suitability of the model for long-acting formulations in a 150-day experiment with triamcinolone acetonide suspension. The suspension displayed similar elimination trend as has been observed in rabbits. We believe this system can lead the way in introducing site-specific drug release testing for the intravitreal route.
Authors
- Amir Sadeghi (ORCID: https://orcid.org/0000-0002-0834-9851)
- Jarmo T. Laitinen (ORCID: https://orcid.org/0000-0002-9490-3686)
- Iuliia Pilipenko (ORCID: https://orcid.org/0000-0001-6202-8031)
- Eva M. del Amo (ORCID: https://orcid.org/0000-0002-5705-4515)
- Timo Sorsa (ORCID: https://orcid.org/0000-0001-7914-3052)
- Arto Urtti (ORCID: https://orcid.org/0000-0001-6064-3102)
- Astrid Subrizi (ORCID: https://orcid.org/0000-0003-2170-4333)
Institutions
- University of Eastern Finland (FI)
Publication Details
- Journal
- Journal of Controlled Release
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1016/j.jconrel.2025.113823
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.41